Compare ATHM & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATHM | STOK |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2013 | 2019 |
| Metric | ATHM | STOK |
|---|---|---|
| Price | $22.74 | $29.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $28.00 | ★ $39.20 |
| AVG Volume (30 Days) | 656.0K | ★ 753.8K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 9.83% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.77 | $77.49 |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $15.57 | $12.41 |
| 52 Week High | $29.92 | $40.22 |
| Indicator | ATHM | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 70.23 | 43.36 |
| Support Level | $21.78 | $27.97 |
| Resistance Level | $23.96 | $33.51 |
| Average True Range (ATR) | 0.78 | 1.61 |
| MACD | 0.10 | -0.07 |
| Stochastic Oscillator | 78.53 | 33.02 |
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent, and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead-generation service provider in China's online auto platform media advertising market, in terms of media services and lead-generation revenue.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.